oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment
Department of Medical Sciences, Uppsala University, Uppsala University Hospital, Uppsala, Sweden.
Department of Medical Sciences, Uppsala University, Uppsala University Hospital, Uppsala, Sweden; Astra Zeneca Research & Development Mölndal, Mölndal, Sweden.
Department of Medical Sciences, Uppsala University, Uppsala University Hospital, Uppsala, Sweden.
Uppsala Clinical Research Center (UCR), Uppsala University, Uppsala, Sweden.
Show others and affiliations
2004 (English)In: BMC Cardiovascular Disorders, ISSN 1471-2261, E-ISSN 1471-2261, Vol. 4, no 1, article id 16Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Dyslipidemia has been associated with hypertension. The present study explored if polymorphisms in genes encoding proteins in lipid metabolism could be used as predictors for the individual response to antihypertensive treatment.

METHODS: Ten single nucleotide polymorphisms (SNP) in genes related to lipid metabolism were analysed by a microarray based minisequencing system in DNA samples from ninety-seven hypertensive subjects randomised to treatment with either 150 mg of the angiotensin II type 1 receptor blocker irbesartan or 50 mg of the beta1-adrenergic receptor blocker atenolol for twelve weeks.

RESULTS: The reduction in blood pressure was similar in both treatment groups. The SNP C711T in the apolipoprotein B gene was associated with the blood pressure response to irbesartan with an average reduction of 19 mmHg in the individuals carrying the C-allele, but not to atenolol. The C16730T polymorphism in the low density lipoprotein receptor gene predicted the change in systolic blood pressure in the atenolol group with an average reduction of 14 mmHg in the individuals carrying the C-allele.

CONCLUSIONS: Polymorphisms in genes encoding proteins in the lipid metabolism are associated with the response to antihypertensive treatment in a drug specific pattern. These results highlight the potential use of pharmacogenetics as a guide for individualised antihypertensive treatment, and also the role of lipids in blood pressure control.

Place, publisher, year, edition, pages
BioMed Central, 2004. Vol. 4, no 1, article id 16
National Category
Medical and Health Sciences Cardiac and Cardiovascular Systems Medical Genetics
Identifiers
URN: urn:nbn:se:oru:diva-69390DOI: 10.1186/1471-2261-4-16PubMedID: 15453913OAI: oai:DiVA.org:oru-69390DiVA, id: diva2:1254532
Available from: 2018-10-09 Created: 2018-10-09 Last updated: 2018-10-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Kurland, Lisa

Search in DiVA

By author/editor
Kurland, Lisa
In the same journal
BMC Cardiovascular Disorders
Medical and Health SciencesCardiac and Cardiovascular SystemsMedical Genetics

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 72 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf